Jazz Pharmaceuticals trades at attractive risk/reward, says Piper Jaffray Piper Jaffray believes Jazz Pharmaceuticals' acquisition of the U.S. rights to Defitelio makes the company's long-term growth story even more attractive. Piper says Jazz shares trade at an attractive risk/reward and it reiterates an Overweight rating on the name with a $200 price target.
BMO's pharma predictions for rest of year include take on Mylan, Perrigo BMO Capital analyst David Maris rolled out his rest of year predictions for the Specialty Pharmaceuticals space. Among them is his belief that Mylan (MYL) will be unsuccessful in acquiring Perrigo (PRGO). Perrigo will either be acquired by another company or make an acquisition itself, Maris tells investors in a research note. His other predictions include Jazz Pharmaceuticals (JAZZ) proving to be a good buying opportunity amidst the current negative sentiment and ZS Pharma (ZSPH) offering upside following the recent pullback given the potential for a near-term buyout and prospects for its "best in class drug for hyperkalemia" winning approval in 2016.